Biotech Values

[AlpineBV_Miller]

"The SPARC data to be presented at upcoming medical conferences will show that Satra had an excellent safety profile for a chemo drug—much superior to Taxotere and to other platinum drugs."

So are these data different than the safety data presented at the PCa conference a few weeks back? Those data were as expected for a platinum drug and had more toxicity than Taxotere. The oral is more convenient, so satraplatin will be used instead of other platinums but the side effect profile means it is no danger to Taxotere -- unless I missed something.